AnaptysBio

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
Clinical Trials Arena
Wed, 02/12/25 - 09:29 pm
AnaptysBio
rheumatoid arthritis
rosinilimab
clinical trials
AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial
Fierce Biotech
Wed, 02/12/25 - 11:12 am
AnaptysBio
rosnilimab
rheumatoid arthritis
clinical trials
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
Fierce Biotech
Wed, 12/11/24 - 11:27 am
AnaptysBio
clinical trials
eczema
atopic dermatitis
ANB032
Top five biopharma companies hiring in San Diego
BioSpace
Thu, 04/11/24 - 10:55 am
San Diego
biotech
hirings
Avidity Biosciences
Element Biosciences
AnaptysBio
Fate Therapeutics
Takeda
AnapstysBio’s imsidolimab Phase III trial’s results can bring it closer to approval
Clinical Trials Arena
Tue, 10/31/23 - 11:26 am
AnaptysBio
clinical trials
generalized pustular psoriasis
imsidolimab
Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal
Fierce Biotech
Mon, 10/9/23 - 10:11 am
AnaptysBio
generalized pustular psoriasis
clinical trials
imsidolimab
Boehringer Ingelheim
Catalysts ahead for the smaller players
EP Vantage
Wed, 12/21/22 - 11:19 am
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy
Fierce Biotech
Thu, 09/1/22 - 10:46 am
AnaptysBio
imsidolimab
hidradenitis suppurativa
Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials
Fierce Biotech
Wed, 06/29/22 - 10:51 am
MiroBio
venture capital
autoimmune disease
Eli Lilly
AnaptysBio
Medicxi
OrbiMed
AnaptysBio CEO Exits After Decade in the Role
BioSpace
Tue, 03/22/22 - 11:23 pm
AnaptysBio
Hamza Suria
Pharma CEOs
The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties
Endpoints
Tue, 10/26/21 - 10:46 am
AnaptysBio
Jemperli
GSK
AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure
Seeking Alpha
Tue, 03/9/21 - 10:55 am
AnaptysBio
imsidolimab
clinical trials
palmoplantar pustulosis
With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy
Endpoints
Mon, 10/26/20 - 11:15 am
AnaptysBio
GSK
Tesaro
Zejula
AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future
Endpoints
Mon, 08/10/20 - 11:01 am
AnaptysBio
rhinosinusitis
etokimab
clinical trials
nasal polyps
Here's Why AnaptysBio Rose 22.1% in May
Motley Fool
Tue, 06/9/20 - 11:26 pm
AnaptysBio
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Motley Fool
Mon, 03/16/20 - 10:31 am
pharma stocks
AnaptysBio
Bluebird Bio
Exelixis
COVID-19
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Thu, 12/5/19 - 10:15 am
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy
Fierce Biotech
Thu, 11/14/19 - 10:23 am
Stanford University
AnaptysBio
peanut allergy
etokimab
AnaptysBio shares collapse after 'worst case scenario' for key drug
Biopharma Dive
Sun, 11/10/19 - 07:52 pm
AnaptysBio
etokimab
clinical trials
AnaptysBio Prepares for a Potential Gear Shift
Yahoo/Motley Fool
Sun, 08/11/19 - 01:25 pm
AnaptysBio
earnings
etokimab

Pages